Organ function separates obesity groups with different mortality risks
In China, the United Kingdom, the United States and Spain, a peer-reviewed observational study tested obesity categories using data from 844,108 adults. Body measurements combined with organ function distinguished clinical from preclinical obesity. Clinical obesity was associated with higher mortality, while most participants initially in the preclinical category did not progress to clinical obesity during a decade of follow-up.
Science··Night
Body measurements change who enters the obesity category
A peer-reviewed observational study has tested an obesity classification framework using data from 844,108 adults in China, the United Kingdom, the United States and Spain. The framework combines body measurements with organ function, distinguishing clinical obesity from a preclinical category. Those categories had different associations with mortality, with clinical obesity linked to the higher risk.[1], [2]
Researchers applied a framework proposed in 2025 to existing cohort records. Waist circumference and waist-to-height ratio supplement body mass index, which uses weight and height. Combining measurements changes the classification in both directions: some people identified by body mass index alone do not meet the combined criteria, while others it misses do. Overall, the additional measurements enlarge the group classified as having obesity, without assigning current organ damage to everyone in it.[1]
Organ function distinguishes clinical and preclinical states
Clinical obesity combines excess adiposity with organ dysfunction. The preclinical category describes excess adiposity with relatively preserved function. Organ dysfunction was largely identified through administrative diagnostic codes rather than direct clinical adjudication. The cohorts did not all contain the same indicators, creating differences in how sensitively the categories could be detected. The attribution method estimates relationships at population level and cannot attribute a particular individual’s organ disorder to excess adiposity alone.[1]
Most preclinical participants remain in that state over a decade
Most participants who began in the preclinical category did not develop clinical obesity during ten years of follow-up. Progression was therefore not inevitable within that period, although the finding does not establish an absence of risk. The US All of Us Research Program had a shorter observation period, so progression in that cohort was assessed over four years rather than ten. Follow-up lengths must remain distinct when comparing the populations.[1]
Mortality comparisons support different prognostic implications for the two categories. Age, other illnesses and measurement differences remain relevant in this retrospective observational analysis. It did not test whether adopting the definition or offering a particular treatment improves outcomes. Prospective studies with direct clinical assessments are needed to refine classification and progression estimates, and a category label by itself was not established as a sufficient rule for deciding access to treatment.[1]
